{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:13:35Z","timestamp":1757621615617,"version":"3.44.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"International Research Support Initiative Program (IRSIP) Higher Education Commission, Pakistan"},{"DOI":"10.13039\/100008697","name":"University of Karachi","doi-asserted-by":"publisher","award":["Dean of Science Research Grant"],"award-info":[{"award-number":["Dean of Science Research Grant"]}],"id":[{"id":"10.13039\/100008697","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"DOI":"10.1186\/s12920-025-02159-8","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T19:58:56Z","timestamp":1754337536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular landscape of non-driver genes in myeloproliferative neoplasms through 333 cancer genes panel: Insights to reveal in Pakistan"],"prefix":"10.1186","volume":"18","author":[{"given":"Munazza","family":"Rashid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rifat Zubair","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Asad","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samina Naz","family":"Mukry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uzma","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Nadeem","family":"Asghar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"issue":"1","key":"2159_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","volume":"1","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Pardanani A. Myeloproliferative neoplasms: A contemporary review. JAMA Oncol. 2015;1(1):97\u2013105.","journal-title":"JAMA Oncol"},{"issue":"5","key":"2159_CR2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/ajh.23678","volume":"89","author":"P Guglielmelli","year":"2014","unstructured":"Guglielmelli P, Nangalia J, Green AR, Vannucchi AM. CALR mutations in myeloproliferative neoplasms: Hidden behind the reticulum. Am J Hematol. 2014;89(5):453\u20136.","journal-title":"Am J Hematol"},{"issue":"12","key":"2159_CR3","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1038\/leu.2017.169","volume":"31","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31(12):2726\u201331.","journal-title":"Leukemia"},{"issue":"9","key":"2159_CR4","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1182\/blood-2014-03-560227","volume":"124","author":"L Malcovati","year":"2014","unstructured":"Malcovati L, Papaemmanuil E, Ambaglio I, Elena C, Gall\u00ec A, Della Porta MG, et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood. 2014;124(9):1513\u201321.","journal-title":"Blood"},{"key":"2159_CR5","doi-asserted-by":"crossref","unstructured":"Alduaij W, McNamara CJ, Schuh A, Arruda A, Sukhai M, Kanwar N, et al. Clinical utility of next-generation sequencing in the management of myeloproliferative Neoplasms: A single-center experience. HemaSphere. 2018;2(3).","DOI":"10.1097\/HS9.0000000000000044"},{"issue":"2","key":"2159_CR6","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a034876","volume":"10","author":"AE Marneth","year":"2020","unstructured":"Marneth AE, Mullally A. The molecular genetics of myeloproliferative neoplasms. Cold Spring Harb Perspect Med. 2020;10(2): a034876.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"2159_CR7","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/leu.2010.69","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128\u201338.","journal-title":"Leukemia"},{"issue":"6","key":"2159_CR8","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","volume":"129","author":"E Rumi","year":"2017","unstructured":"Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129(6):680\u201392.","journal-title":"Blood"},{"issue":"1","key":"2159_CR9","first-page":"110","volume":"2018","author":"M Ciboddo","year":"2018","unstructured":"Ciboddo M, Mullally A. JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy. Hematol (United States). 2018;2018(1):110\u20137.","journal-title":"Hematol (United States)"},{"key":"2159_CR10","doi-asserted-by":"crossref","unstructured":"Skov V. Next Generation Sequencing in MPNs. Lessons from the past and prospects for use as predictors of prognosis and treatment responses. Cancers. 2020;12(8):2194.","DOI":"10.3390\/cancers12082194"},{"issue":"3","key":"2159_CR11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/leu.2016.263","volume":"31","author":"A Stengel","year":"2017","unstructured":"Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: An analysis of 3307 cases. Leukemia. 2017;31(3):705\u201311.","journal-title":"Leukemia"},{"issue":"15","key":"2159_CR12","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and Personalized Prognosis in Myeloproliferative Neoplasms. N Engl J Med. 2018;379(15):1416\u201330.","journal-title":"N Engl J Med"},{"key":"2159_CR13","doi-asserted-by":"crossref","unstructured":"Ross DM, Thomson C, Hamad N, Lane SW, Manos K, Grigg AP, et al. Myeloid somatic mutation panel testing in myeloproliferative neoplasms. Vol. 53, Pathology. 2021.","DOI":"10.1016\/j.pathol.2021.01.003"},{"issue":"23","key":"2159_CR14","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.1182\/blood.V126.23.5215.5215","volume":"126","author":"M Rashid","year":"2015","unstructured":"Rashid M, Ahmed RZ, Ahmed S, Nadeem M, Ahmed N, Shamsi T. A Case Report on Coexisting JAK2 V617F and Calr exon 9 Mutation in Essential Thrombocythemia. Blood. 2015;126(23):5215\u20135215.","journal-title":"Blood"},{"key":"2159_CR15","doi-asserted-by":"crossref","unstructured":"Zaidi U, Sufaida G, Rashid M, Kaleem B, Maqsood S, Mukry SN, et al. A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients. BMC Cancer. 2020;20(1).","DOI":"10.1186\/s12885-020-6700-3"},{"issue":"April","key":"2159_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5045\/br.2021.2020325","volume":"56","author":"SE Lee","year":"2021","unstructured":"Lee SE. Disease modifying agents of myeloproliferative neoplasms: A review. Blood Res. 2021;56(April):26\u201333.","journal-title":"Blood Res"},{"issue":"15","key":"2159_CR17","first-page":"1416","volume":"379","author":"J Grinfeld","year":"2020","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Cantrill R, Godfrey AL, et al. Europe PMC Funders Group Disease heterogeneity and personalized prognosis in myeloproliferative neoplasms. 2020;379(15):1416\u201330.","journal-title":"Europe PMC Funders Group Disease heterogeneity and personalized prognosis in myeloproliferative neoplasms"},{"issue":"1","key":"2159_CR18","first-page":"170","volume":"17","author":"J Tan","year":"2021","unstructured":"Tan J, Chow YP, Abidin NZ, Veerakumarasivam A, Wong CL. From driver mutations to genomic classification: Current & future perspectives on myeloproliferative Neoplasms. Malaysian J Med Heal Sci. 2021;17(1):170\u201383.","journal-title":"Malaysian J Med Heal Sci"},{"issue":"6","key":"2159_CR19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667\u201379.","journal-title":"Blood"},{"key":"2159_CR20","doi-asserted-by":"crossref","unstructured":"Magali Olivier MH and PH 1Group. TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use. Cold Spring Harb Perspect Biol 2010;2a001008. 2010;220(1):651\u20134.","DOI":"10.1101\/cshperspect.a001008"},{"issue":"5","key":"2159_CR21","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1056\/NEJMc1012718","volume":"364","author":"A Harutyunyan","year":"2011","unstructured":"Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. p53 Lesions in Leukemic Transformation. N Engl J Med. 2011;364(5):488\u201390.","journal-title":"N Engl J Med"},{"key":"2159_CR22","doi-asserted-by":"crossref","unstructured":"Palumbo GA, Stella S, Pennisi MS, Pirosa C, Fermo E, Fabris S, et al. The role of new technologies in myeloproliferative neoplasms. Front Oncol. 2019;9.","DOI":"10.3389\/fonc.2019.00321"},{"issue":"1","key":"2159_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1(1):21\u201330.","journal-title":"Blood Adv"},{"issue":"2","key":"2159_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Finke CM, Elala Y, Hanson CA, Ketterling RP, et al. Targeted deep sequencing in primary myelofibrosis. Blood Adv. 2016;1(2):105\u201311.","journal-title":"Blood Adv"},{"issue":"3","key":"2159_CR25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/bjh.14269","volume":"175","author":"S Delic","year":"2016","unstructured":"Delic S, Rose D, Kern W, Nadarajah N, Haferlach C, Haferlach T, et al. Application of an ngs-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. Br J Haematol. 2016;175(3):419\u201326.","journal-title":"Br J Haematol"},{"issue":"2","key":"2159_CR26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/leu.2017.230","volume":"32","author":"B Kubesova","year":"2017","unstructured":"Kubesova B, Pavlova S, Malcikova J, Kabathova J, Radova L, Tom N, et al. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: Association with age, Hydroxyurea Administration, disease type and JAK2 mutational status. Leukemia. 2017;32(2):450\u201361.","journal-title":"Leukemia"},{"key":"2159_CR27","doi-asserted-by":"crossref","unstructured":"Weng Y, Lu L, Yuan G, Guo J, Zhang Z, Xie X, et al. P53 codon 72 polymorphism and Hematological Cancer Risk: An update meta-analysis. PLoS ONE. 2012;7(9).","DOI":"10.1371\/journal.pone.0045820"},{"key":"2159_CR28","doi-asserted-by":"crossref","unstructured":"Chen Y, Talukder R, Merritt BY, King KY, Kimmel M, Rivero G, et al. Genomic trajectory in leukemogenesis of myeloproliferative neoplasms: A case report. BMC Med Genomics. 2021;14(1).","DOI":"10.1186\/s12920-021-00986-z"},{"issue":"6","key":"2159_CR29","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1600-0463.2011.02737.x","volume":"119","author":"J Yun","year":"2011","unstructured":"Yun J, Lee J, Jang J, Lee EJ, Jang KT, Kim JH, et al. KIT amplification and gene mutations in acral\/mucosal melanoma in Korea. APMIS. 2011;119(6):330\u20135.","journal-title":"APMIS"},{"issue":"10","key":"2159_CR30","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.leukres.2005.12.020","volume":"30","author":"A Fontalba","year":"2006","unstructured":"Fontalba A, Agirre X, Real PJ, Richard C, Prosper F, Fernandez-Luna JL. Identification of c-Kit gene mutations in patients with polycythemia vera. Leuk Res. 2006;30(10):1325\u20136.","journal-title":"Leuk Res"},{"issue":"1","key":"2159_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/10428190802517773","volume":"50","author":"HR Shakah","year":"2009","unstructured":"Shakah HR, Awidi A, Naffa RG, Ismail SI. Screening patients with polycythemia vera for c-Kit mutations. Leuk Lymphoma. 2009;50(1):127\u20139.","journal-title":"Leuk Lymphoma"},{"key":"2159_CR32","unstructured":"Dean L. Irinotecan therapy and UGT1A1 genotype. In: Medical Genetics Summaries. 2015. National Center for Biotechnology Information (US). 2012. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK294473\/#__NBK294473_dtls_. Accessed 7 Jan 2024."},{"issue":"3","key":"2159_CR33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/FPC.0000000000000024","volume":"24","author":"JM Barbarino","year":"2014","unstructured":"Barbarino JM, Haidar CE, Klein TE, Altman RB. PharmGKB summary: Very important pharmacogene information for UGT1A1. Pharmacogenet Genomics. 2014;24(3):177\u201383.","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"2159_CR34","first-page":"567","volume":"25","author":"XX Li","year":"2017","unstructured":"Li XX, Shi J, Huang ZD, Shao YQ, Nie N, Zhang J, et al. Clinical Characteristics and Gene Mutations of Gilbert Syndrome Complicated with Myeloproliferative Neoplasm. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017;25(2):567\u201371.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"2159_CR35","doi-asserted-by":"crossref","unstructured":"Chen P, Zhu K-W, Zhang D-Y, Yan H, Liu H, Liu Y-L, et al. Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens. J Transl Medicine. 2018;16(1).","DOI":"10.1186\/s12967-018-1579-3"},{"issue":"4","key":"2159_CR36","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s13691-012-0045-y","volume":"1","author":"K Takada","year":"2012","unstructured":"Takada K, Sato T, Iyama S, Ono K, Kamihara Y, Murase K, et al. UGT1A1*28 and *6 polymorphisms and nilotinib-induced unconjugated hyperbilirubinemia in a Japanese patient with chronic myelogenous leukemia. Int Cancer Conf J. 2012;1(4):220\u20133.","journal-title":"Int Cancer Conf J"},{"issue":"6","key":"2159_CR37","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/ahg.12039","volume":"77","author":"S Khan","year":"2013","unstructured":"Khan S, Irfan M, Sher G, Zubaida B, Alvi MA, Yasinzai M, et al. UGT1A1 gene mutations in Pakistani children suffering from inherited nonhemolytic unconjugated hyperbilirubinemias. Ann Hum Genet. 2013;77(6):482\u20137.","journal-title":"Ann Hum Genet"},{"key":"2159_CR38","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.2147\/NDT.S230348","volume":"15","author":"AH Arab","year":"2019","unstructured":"Arab AH, Elhawary NA. Methylenetetrahydrofolate reductase gene variants confer potential vulnerability to autism spectrum disorder in a Saudi community. Neuropsychiatr Dis Treat. 2019;15:3569\u201381.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"2159_CR39","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1309\/LM7BFTEZ98ZZMWPQ","volume":"42","author":"F Atashrazm","year":"2011","unstructured":"Atashrazm F, Zaker F, Aghaeipour M, Pazhakh V. Polymorphisms of the methylene tetrahydrofolate reductase and susceptibility to acute lymphoblastic leukemia in children. Lab Med. 2011;42(5):275\u20139.","journal-title":"Lab Med"},{"issue":"July","key":"2159_CR40","first-page":"1","volume":"9","author":"SM Baba","year":"2019","unstructured":"Baba SM, Shah ZA, Javaid K, Pandith AA, Rasool J, Geelani SA, et al. Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphic sequence variations influences the susceptibility to chronic myeloid leukemia in Kashmiri population. Front Oncol. 2019;9(July):1\u20138.","journal-title":"Front Oncol"},{"key":"2159_CR41","doi-asserted-by":"crossref","unstructured":"Jiang N, Zhu X. The relationship between methylenetetrahydrofolate reductase polymorphism and hematological malignancy. Clin Lab. 2014;60(05\/2014).","DOI":"10.7754\/Clin.Lab.2013.130447"},{"issue":"1","key":"2159_CR42","first-page":"e9","volume":"35","author":"AP Trifa","year":"2012","unstructured":"Trifa AP, Cucuianu A, Popp RA, Costache RM, Coad\u0103 CA, Sarca AD, et al. Analysis of the MTHFR (methylenetetrahydrofolate reductase) 677 C>T and 1298 A>C polymorphisms in BCR-ABL-negative myeloproliferative neoplasms. Int J Lab Hemat. 2012;35(1):e9\u201312.","journal-title":"Int J Lab Hemat"},{"issue":"4","key":"2159_CR43","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.7314\/APJCP.2012.13.4.1599","volume":"13","author":"M Akram","year":"2012","unstructured":"Akram M, Malik FA, Kayani MA. Mutational analysis of the MTHFR gene in breast cancer patients of Pakistani population. Asian Pacific J Cancer Prev. 2012;13(4):1599\u2013603.","journal-title":"Asian Pacific J Cancer Prev"},{"issue":"1","key":"2159_CR44","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2217\/pme-2018-0045","volume":"16","author":"N Ullah","year":"2019","unstructured":"Ullah N, Mansoor A, Micheal S, Mirza B, Qamar R, Mazhar K, et al. MTHFR polymorphisms as risk for male infertility in Pakistan and its comparison with socioeconomic status in the world. Per Med. 2019;16(1):35\u201349.","journal-title":"Per Med"},{"issue":"1","key":"2159_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1515\/bjmg-2016-0007","volume":"19","author":"M Irfan","year":"2016","unstructured":"Irfan M, Ismail M, Azhar Beg M, Shabbir A, Rashid Kayani A, Kaukab RG. Association of the MTHFR C677T (rs1801133) polymorphism with idiopathic male infertility in a local Pakistani population. Balk J Med Genet. 2016;19(1):51\u201362.","journal-title":"Balk J Med Genet"},{"issue":"10","key":"2159_CR46","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1007\/s10620-008-0225-y","volume":"53","author":"Y Bayraktar","year":"2008","unstructured":"Bayraktar Y, Harmanci O, B\u00fcy\u00fckasik Y, Shorbagi AI, Sungur AH, Boylu CA, et al. JAK2V617F mutation in patients with portal vein thrombosis. Dig Dis Sci. 2008;53(10):2778\u201383.","journal-title":"Dig Dis Sci"},{"issue":"7","key":"2159_CR47","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1177\/0009922812447280","volume":"52","author":"MR Ehmann","year":"2012","unstructured":"Ehmann MR, Goodenough CJ, Lotterman CD, Warrier RP. Concurrent JAK2V617F mutation and MTHFRC677T homozygosity in an adolescent with polycythemia vera: Case report and discussion. Clin Pediatr (Phila). 2012;52(7):671\u20134.","journal-title":"Clin Pediatr (Phila)"},{"key":"2159_CR48","doi-asserted-by":"crossref","unstructured":"Kaur J, Sambyal V, Guleria K, Singh NR, Uppal MS, Manjari M, et al. Association of XRCC1, XRCC2 and XRCC3 gene polymorphism with esophageal cancer risk. Clin Exp Gastroenterol. 2020;13 73\u201386.","DOI":"10.2147\/CEG.S232961"},{"key":"2159_CR49","doi-asserted-by":"crossref","unstructured":"Ali O Zcan, Mustafa P, Ay\u015fe GT, E K, Cihangir O zk\u0131nay, Filiz O zdemir, et al. Polymorphisms of the DNA repair gene XPD (751) and XRCC1 (399) correlates with risk of hematological malignancies in Turkish population. African J Biotechnology. 2011;10(44):8860\u201370.","DOI":"10.5897\/AJB10.1839"},{"issue":"3","key":"2159_CR50","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1179\/1607845412Y.0000000040","volume":"18","author":"S Annamaneni","year":"2013","unstructured":"Annamaneni S, Gorre M, Kagita S, Addepalli K, Digumarti RR, Satti V, et al. Association of XRCC1 gene polymorphisms with chronic myeloid leukemia in the population of Andhra Pradesh. India Hematology. 2013;18(3):163\u20138.","journal-title":"India Hematology"},{"issue":"5","key":"2159_CR51","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.leukres.2011.10.012","volume":"36","author":"N \u00d6zdemir","year":"2012","unstructured":"\u00d6zdemir N, Celkan T, Bari\u015f S, Batar B, G\u00fcven M. DNA repair gene XPD and XRCC1 polymorphisms and the risk of febrile neutropenia and mucositis in children with leukemia and lymphoma. Leuk Res. 2012;36(5):565\u20139.","journal-title":"Leuk Res"},{"issue":"6","key":"2159_CR52","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.1007\/s13277-015-3099-6","volume":"36","author":"L Du","year":"2015","unstructured":"Du L, Liu Y, Xue P, Song C, Shen J, He Q, et al. The ARG399GLN polymorphism in the XRCC1 gene is associated with increased risk of hematological malignancies. Tumor Biol. 2015;36(6):4545\u201354.","journal-title":"Tumor Biol"},{"issue":"1","key":"2159_CR53","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000477109","volume":"42","author":"R Sarwar","year":"2017","unstructured":"Sarwar R, Mahjabeen I, Bashir K, Saeed S, Kayani MA. Haplotype based analysis of XRCC3 gene polymorphisms in thyroid cancer. Cell Physiol Biochem. 2017;42(1):22\u201333.","journal-title":"Cell Physiol Biochem"},{"key":"2159_CR54","first-page":"1153","volume":"17","author":"S Yousaf","year":"2011","unstructured":"Yousaf S, Khan MI, Micheal S, Akhtar F, Ali S, Riaz M, et al. XRCC1 and XPD DNA repair gene polymorphisms: A potential risk factor for glaucoma in the Pakistani population. Mol Vis. 2011;17:1153\u201363.","journal-title":"Mol Vis"},{"issue":"3","key":"2159_CR55","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s10792-017-0574-7","volume":"38","author":"T Khosa","year":"2017","unstructured":"Khosa T, Aslam S, Mustafa S, Akbar A, Shaikh RS, Iqbal F. Association of Single Nucleotide Polymorphisms in XRCC1 (194) and XPD (751) with age-related cataract. Int Ophthalmol. 2017;38(3):1135\u201346.","journal-title":"Int Ophthalmol"},{"issue":"9","key":"2159_CR56","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.2217\/pgs.11.72","volume":"12","author":"U Amstutz","year":"2011","unstructured":"Amstutz U, Froehlich TK, Largiadr CR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics. 2011;12(9):1321\u201336.","journal-title":"Pharmacogenomics"},{"issue":"2","key":"2159_CR57","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2017","unstructured":"Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther. 2017;103(2):210\u20136.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2159_CR58","doi-asserted-by":"publisher","first-page":"782","DOI":"10.4103\/0973-1482.148685","volume":"12","author":"GY Li","year":"2016","unstructured":"Li GY, Duan JF, Li WJ, Liu T. DPYD\u22172A\/\u22175A\/\u22179A and UGT1A1\u22176\/\u221728 polymorphisms in Chinese colorectal cancer patients. J Cancer Res Ther. 2016;12(2):782\u20136.","journal-title":"J Cancer Res Ther"},{"key":"2159_CR59","unstructured":"Dean L, Kane M, Pratt VM, Scott SA, Primohamed M, Esquivel B. Fluorouracil Therapy and DPYD Genotype. In: Medical Genetics Summaries. 2016. National Center for Biotechnology Information (US). 2012. https:\/\/pubmed.ncbi.nlm.nih.gov\/28520376\/. Accessed 7 Jan 2024."},{"key":"2159_CR60","doi-asserted-by":"crossref","unstructured":"Del Re M, Michelucci A, Di Leo A, Cantore M, Bordonaro R, Simi P, et al. Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients EPMA J. 2015;6(1).","DOI":"10.1186\/s13167-015-0039-x"},{"issue":"6","key":"2159_CR61","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/humu.9201","volume":"22","author":"E Gross","year":"2003","unstructured":"Gross E, Ullrich T, Seck K, Mueller V, de Wit M, von Schilling C, et al. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum Mutat. 2003;22(6):498\u2013498.","journal-title":"Hum Mutat"},{"issue":"6","key":"2159_CR62","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2217\/pgs.09.28","volume":"10","author":"U Amstutz","year":"2009","unstructured":"Amstutz U, Farese S, Aebi S, Largiad\u00e8r CR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: A haplotype assessment. Pharmacogenomics. 2009;10(6):931\u201344.","journal-title":"Pharmacogenomics"},{"issue":"4","key":"2159_CR63","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1365-2125.2007.03052.x","volume":"65","author":"MJ Bijl","year":"2008","unstructured":"Bijl MJ, Visser LE, Hofman A, Vulto AG, Van Gelder T, Stricker BH, et al. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol. 2008;65(4):558\u201364.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2159_CR64","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/gim.2016.80","volume":"19","author":"A Gaedigk","year":"2017","unstructured":"Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Steven LJ. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017;19(1):69\u201376.","journal-title":"Genet Med"},{"issue":"5","key":"2159_CR65","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1182\/blood.V93.5.1496","volume":"93","author":"M Krajinovic","year":"1999","unstructured":"Krajinovic M, Labuda D, Richer C, Karimi S, Sinnett D. Susceptibility to childhood acute lymphoblastic leukemia: Influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood. 1999;93(5):1496\u2013501.","journal-title":"Blood"},{"issue":"2","key":"2159_CR66","first-page":"77","volume":"6","author":"S Nida","year":"2017","unstructured":"Nida S, Javid B, Akbar M, Idrees S, Adil W, Ahmad GB. Gene variants of CYP1A1 and CYP2D6 and the risk of childhood acute lymphoblastic leukaemia; outcome of a case control study from Kashmir. India Mol Biol Res Commun. 2017;6(2):77\u201384.","journal-title":"India Mol Biol Res Commun"},{"issue":"3","key":"2159_CR67","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/ajh.20434","volume":"81","author":"M Aydin-Sayitogiu","year":"2006","unstructured":"Aydin-Sayitogiu M, Hatirnaz O, Erensoy N, Ozbek U. Role of CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias. Am J Hematol. 2006;81(3):162\u201370.","journal-title":"Am J Hematol"},{"key":"2159_CR68","doi-asserted-by":"crossref","unstructured":"Okat Z, U\u00e7ar \u00c7ift\u00e7i K, Yaman K, Toplayici S, Kurt E, Taga Y. CYP 2D6*4 polymorphism in polycythemia vera patients in Turkish population. Marmara Med J. 2018:5\u201311.","DOI":"10.5472\/marumj.430790"},{"issue":"10","key":"2159_CR69","doi-asserted-by":"publisher","first-page":"7413","DOI":"10.1007\/s11033-020-05796-7","volume":"47","author":"A Daglar-Aday","year":"2020","unstructured":"Daglar-Aday A, Akadam-Teker B, Yonal-Hindilerden I, Dermenci H, Sahin E, Hindilerden F, et al. The impact of CYP2D6*4 and GSTP1 ile105val polymorphisms on the susceptibility to develop BCR-ABL1 negative myeloproliferative neoplasms. Mol Biol Rep. 2020;47(10):7413\u201320.","journal-title":"Mol Biol Rep"},{"issue":"2","key":"2159_CR70","first-page":"739","volume":"33","author":"A Ullah","year":"2020","unstructured":"Ullah A, Riaz S, Siddiqi S, Mazhar K, Mansoor A. CYP2D6*4 null allele frequency in sixteen Pakistani ethnic groups. Pak J Pharm Sci. 2020;33(2):739\u201343.","journal-title":"Pak J Pharm Sci"},{"issue":"6","key":"2159_CR71","first-page":"1303","volume":"9","author":"C Mosnier","year":"2025","unstructured":"Mosnier C, Bellal S, Cottin L, Boyer F, Lemoine S, Bachelot A, et al. Relationship between additional mutations at diagnosis and treatment response in patients with essential thrombocythemia Blood Adv. 2025;9(6):1303\u201311.","journal-title":"Relationship between additional mutations at diagnosis and treatment response in patients with essential thrombocythemia Blood Adv"},{"key":"2159_CR72","doi-asserted-by":"crossref","unstructured":"Fathima S, Abdelmagid M, Alsugair A, Begna KH, Al-Kali A, Mangaonkar A, et al. Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases.\u00a0Am J Hematol. 2025.","DOI":"10.1002\/ajh.27670"},{"issue":"14","key":"2159_CR73","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1200\/JCO.20.02341","volume":"39","author":"DA Sallman","year":"2021","unstructured":"Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, et al. Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol. 2021;39(14):1584\u201394.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2159_CR74","first-page":"S408","volume":"24","author":"B Inna","year":"2024","unstructured":"Inna B, Aziza M, Nikzan K. MPN-010 Study of Thrombophilia Genes in Patients with Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2024;24(1):S408.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"2159_CR75","doi-asserted-by":"publisher","first-page":"5065","DOI":"10.1182\/blood.V120.21.5065.5065","volume":"120","author":"E Papadakis","year":"2012","unstructured":"Papadakis E, Papageorgiou V, Tsepanis K, Theocharidou D, Papadopoulos VK, Georgiou E, et al. Impact of inherited thrombophilia factors on thrombotic risk in patients with newly diagnosed BCR-ABL (-) myeloproliferative disorders: Finally a role of MTHFR-C677T polymorphism? Blood. 2012;120(21):5065.","journal-title":"Blood"},{"issue":"1","key":"2159_CR76","doi-asserted-by":"publisher","first-page":"S365","DOI":"10.1016\/S2152-2650(21)01839-5","volume":"21","author":"E Beleva","year":"2021","unstructured":"Beleva E, Ivanov H, Gogova T, Enchev K, Zheliazkov I, Linev A, et al. MPN-388: Assessment of Prevalence and Risk Factors for Subclinical Splanchnic Thrombosis in Patients with Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2021;21(1):S365\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2159_CR77","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/diagnostics13010163","volume":"13","author":"YC Chia","year":"2023","unstructured":"Chia YC, Asmaa MJS, Ramli M, Woon PY, Johan MF, Hassan R, Islam MA. Molecular genetics of thrombotic myeloproliferative neoplasms: Implications in precision oncology. Diagnostics. 2023;13(1):163.","journal-title":"Diagnostics"},{"issue":"6","key":"2159_CR78","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1200\/JCO.2002.20.6.1692","volume":"20","author":"MC Heinrich","year":"2002","unstructured":"Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002;20(6):1692\u2013703.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2159_CR79","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1182\/blood-2003-06-2071","volume":"103","author":"T Kindler","year":"2004","unstructured":"Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B, et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood. 2004;103(10):3644\u201354.","journal-title":"Blood"},{"issue":"3","key":"2159_CR80","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2217\/pgs.10.19","volume":"11","author":"Y Fujiwara","year":"2010","unstructured":"Fujiwara Y, Minami H. An overview of the recent progress in irinotecan pharmacogenetics. Pharmacogenomics. 2010;11(3):391\u2013406.","journal-title":"Pharmacogenomics"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-025-02159-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-025-02159-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-025-02159-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T14:37:40Z","timestamp":1757342260000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-025-02159-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2159"],"URL":"https:\/\/doi.org\/10.1186\/s12920-025-02159-8","relation":{},"ISSN":["1755-8794"],"issn-type":[{"type":"electronic","value":"1755-8794"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"4 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the ethics committee of NIBD. Informed written consent was obtained from all patients before capturing the data in the electronic database system.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}